S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:SAGE

Sage Therapeutics (SAGE) Earnings Date, Estimates & Call Transcripts

$49.82
+0.26 (+0.52%)
(As of 06/2/2023 ET)
Compare
Today's Range
$48.75
▼
$50.24
50-Day Range
$40.65
▼
$53.38
52-Week Range
$30.67
▼
$54.86
Volume
373,408 shs
Average Volume
505,670 shs
Market Capitalization
$2.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.54
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 1Estimated
Actual EPS
(May. 2)
-$2.46 Beat By $0.04
Consensus EPS
(May. 2)
-$2.50
Last Year's Q2 EPS
(5/3/2022)
-$2.07
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SAGE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SAGE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sage Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($2.48)($2.30)($2.42)
Q2 20234($2.60)($2.54)($2.57)
Q3 20234($2.56)($1.43)($2.21)
Q4 20234($2.36)$1.20($0.66)
FY 202316($10.00)($5.07)($7.85)
Q1 20242($2.51)$0.82($0.85)
Q2 20242($2.45)($2.29)($2.37)
Q3 20242($2.35)($2.16)($2.26)
Q4 20242($2.26)($1.96)($2.11)
FY 20248($9.57)($5.59)($7.58)

SAGE Earnings Date and Information

Sage Therapeutics last released its earnings data on May 2nd, 2023. The biopharmaceutical company reported ($2.46) EPS for the quarter, beating the consensus estimate of ($2.50) by $0.04. The business earned $3.30 million during the quarter, compared to analyst estimates of $2.28 million. Its quarterly revenue was up 120.0% compared to the same quarter last year. Sage Therapeutics has generated ($9.37) earnings per share over the last year (($9.37) diluted earnings per share). Earnings for Sage Therapeutics are expected to decrease in the coming year, from ($8.04) to ($8.08) per share. Sage Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off prior year's report dates.

Sage Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/1/2023
(Estimated)		        
5/2/2023Q1 2023($2.50)($2.46)+$0.04($2.46)$2.28 million$3.30 million    
2/16/2023Q4 2022($2.37)($2.47)($0.10)($2.47)$1.94 million$2.87 million    
11/8/2022Q3 2022($2.16)($2.31)($0.15)($2.31)$1.68 million$1.74 million
8/2/2022Q2 2022($2.16)($2.13)+$0.03($2.13)$1.77 million$1.50 million    
5/3/2022Q1 2022($2.09)($2.07)+$0.02($2.07)$3.23 million$1.58 million    
2/24/2022Q4 2021($2.16)($2.12)+$0.04($2.12)$1.77 million$1.65 million    
11/2/20219/30/2021($1.84)($2.21)($0.37)($2.21)$2.00 million$1.44 million    
8/3/20216/30/2021($1.69)($1.83)($0.14)($1.83)$2.01 million$1.60 million    
5/4/20213/31/2021($1.98)($1.64)+$0.34($1.64)$2.03 million$1.58 million  
2/24/202112/31/2020($2.17)$18.19+$20.36($23.13)$1.86 million$1.69 million  
11/5/20209/30/2020($2.30)($2.03)+$0.27($2.03)$1.85 million$1.64 million  
8/10/20206/30/2020($2.67)($2.63)+$0.04($1.53)$0.88 million$1.09 million  
5/7/2020Q1($3.17)($2.44)+$0.73($2.44)$2.81 million$2.29 million  
2/27/2020Q4($3.62)($3.25)+$0.37($3.25)$3.76 million$1.96 million  
11/12/2019Q3($3.41)($3.48)($0.07)($3.48)$2.52 million$3.57 million  
8/6/2019Q2 2019($3.32)($3.28)+$0.04($3.28)$0.27 million$0.87 million  
5/2/20193/31/2019($3.17)($3.37)($0.20)($3.37)$0.47 million
2/19/201912/31/2018($2.89)($3.38)($0.49)($3.38)$0.27 million  
11/6/2018Q3($2.41)($2.63)($0.22)($2.63)
8/7/2018Q2 2018($1.84)($0.36)+$1.48($0.36)$90.00 million
5/3/2018Q1 2018($1.84)($1.68)+$0.16($1.68)
2/22/2018Q4 2017($1.9810)($1.75)+$0.2310($1.75)
11/2/2017Q3 2017($1.9830)($1.97)+$0.0130($1.97)
8/3/2017Q2 2017($1.63)($1.88)($0.25)($1.88)  
5/9/2017Q1 2017($1.6080)($1.52)+$0.0880($1.52)  
2/23/2017Q4 2016($1.14)($1.50)($0.36)($1.50)
11/3/2016Q3 2016($1.16)($1.15)+$0.01($1.15)
8/9/2016Q2 2016($1.04)($1.08)($0.04)($1.08)
5/5/2016Q1 2016($0.97)($0.97)($0.97)  
2/24/2016Q4 2015($0.91)($0.99)($0.08)($0.99)  
11/5/2015Q3 2015($0.85)($0.84)+$0.01($0.84)
8/12/2015Q2 2015($0.71)($0.90)($0.19)($0.90)
5/14/2015Q1 2015($0.56)($0.66)($0.10)($0.66)
2/27/2015Q414($0.44)($1.57)($1.13)
11/11/2014Q3 2014($0.47)($0.50)($0.03)($0.50)
8/14/2014Q2 2014($0.83)($4.57)($3.74)($4.57)












Sage Therapeutics Earnings - Frequently Asked Questions

When is Sage Therapeutics's earnings date?

Sage Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off last year's report dates. Learn more on SAGE's earnings history.

Did Sage Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Sage Therapeutics (NASDAQ:SAGE) reported ($2.46) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.50) by $0.04. Learn more on analysts' earnings estimate vs. SAGE's actual earnings.

How can I listen to Sage Therapeutics's earnings conference call?

The conference call for Sage Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Sage Therapeutics's conference call transcript?

The conference call transcript for Sage Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Sage Therapeutics generate each year?

Sage Therapeutics (NASDAQ:SAGE) has a recorded annual revenue of $7.69 million.

How much profit does Sage Therapeutics generate each year?

Sage Therapeutics (NASDAQ:SAGE) has a recorded net income of -$532.78 million. SAGE has generated -$9.37 earnings per share over the last four quarters.

What is Sage Therapeutics's EPS forecast for next year?

Sage Therapeutics's earnings are expected to decrease from ($8.04) per share to ($8.08) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:SAGE) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -